Article by Dr. Angela Alexander On Apr 30th, the FDA approved a new first-in-class drug for the treatment of ER+ metastatic breast cancer (MBC). The new drug Vepdegestrant was approved only for patients with tumors that harbor ESR1 mutations, based on results from...
What we don’t know — and why it matters by Terry Arnold On a flight to Cleveland, the woman beside me leaned back in her seat and said in a mocking voice, “She waited too long.” It took every ounce of self-control I had. After about an hour of silence, we had started...
Co authors: Terry Arnold and Stephanie Pilkinton Every December, the global breast cancer community gathers in San Antonio, Texas, for the San Antonio Breast Cancer Symposium (SABCS) — the largest breast cancer research meeting in the world. For those of us focused on...
Featured Author: Stephanie Pilkinton (follow Stephanie at https://substack.com/@sweetteaandscience) The San Antonio Breast Cancer Symposium (SABCS) brings together researchers, clinicians, and advocates from around the world to share the latest advances in breast...
For years, I would wake up early and write about everything people needed to know about inflammatory breast cancer. I wrote about the plans the IBC Network had, why they mattered, and how we needed to execute them. I wrote to educate, to correct misinformation, and to...
